Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
Related Excipient Companies
Excipients by Applications
Global Sales Information
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 6,992
2019 Revenue in Millions : 7,204
Growth (%) : -3
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 907
2019 Revenue in Millions : 827
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 7,523
2020 Revenue in Millions : 6,992
Growth (%) : 8
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 908
2020 Revenue in Millions : 870
Growth (%) : 12
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 252
2021 Revenue in Millions : 0
Growth (%) : New Launch in 2022
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,050
2021 Revenue in Millions : 908
Growth (%) : 16
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 8,249
2021 Revenue in Millions : 7,523
Growth (%) : 10
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 9,009
2022 Revenue in Millions : 8,249
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 627
2022 Revenue in Millions : 252
Growth (%) : 149
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,001
2022 Revenue in Millions : 1,050
Growth (%) : 8
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?